# EDGAR Filing Document

**Accession Number:** 0001896212
**File Stem:** 0001493152-26-023707
**Filing Date:** 2026-5
**Character Count:** 25924
**Document Hash:** 6bca726076e36a0c85cb26fac36859e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-023707.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001493152-26-023707

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20260515

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CDT Equity Inc.
- **CENTRAL INDEX KEY:** 0001896212
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 873272543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41245
- **FILM NUMBER:** 26986704

**BUSINESS ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103
- **BUSINESS PHONE:** (646) 491 9132

**MAIL ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONDUIT PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20230922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Murphy Canyon Acquisition Corp.
- **DATE OF NAME CHANGE:** 20211130

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 15, 2026**

**CDT Equity Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41245** | **87-3272543** |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **4851 Tamiami Trail North, Suite 200, Naples, FL** | **34103** |
| (Address of principal executive offices) | (Zip Code) |

---

**(646) 491-9132**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | CDT | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole warrant exercisable for one share of Common Stock | CDTTW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On May 15, 2026, CDT Equity Inc. (the "Company") entered into the second amendment (the "Amendment No. 2") to that certain directed stock purchase agreement, dated January 16, 2026 (as amended, the "Purchase Agreement"), with an institutional investor (the "Purchaser") relating to an equity line of credit facility (the "ELOC"). Pursuant to Amendment No. 2, the parties mutually agreed to set the gross purchase price to be paid without the consent of the Purchaser at any closing of a regular purchase at $510,000. Amendment No. 2 also extends the Adjustment Period, as defined in the Purchase Agreement, to such time as the Purchaser has entered into committed and binding trades to sell all of the shares it purchased under the Purchase Agreement.

In addition, on May 15, 2026, the Company and the Purchaser entered into an amendment (the "Note Amendment") to that certain Senior Secured Convertible Promissory Note, originally issued on March 3, 2026 (the "Note"). Pursuant to the Note Amendment, 90% of the proceeds raised by the Company in any debt or equity financing or capital-raising transaction, including pursuant to the ELOC, may be retained by the Company, with the remaining 10% required to go towards payment of amounts due under the Note.

Both Amendment No. 2 and the Note Amendment are effective through May 31, 2026, at which point they will no longer modify the Purchase Agreement and Note, respectively.

The foregoing descriptions of Amendment No. 2 and the Note Amendment are qualified in their entirety by reference to Amendment No. 2 and the Note Amendment, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report and are incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Form of Amendment No. 2 to Equity Purchase Agreement, dated May 15, 2026](ex10-1.htm) |
| 10.2 | [Form of Amendment to Senior Secured Convertible Promissory Note, dated May 15, 2026](ex10-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CDT EQUITY INC.** | **CDT EQUITY INC.** |
| May 15, 2026 | By: | */s/ Andrew Regan* |
|  | Name: | Andrew Regan |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

**19505 Biscayne Blvd. ● Suite 2350 ● Aventura, FL 33180 ● legal@ascentpartnersllc.com**

To:

CDT Equity Inc.

4851 Tamiami Trail North, Suite 200

Naples, Florida 34103

Attention: Andrew Regan <br> CEO

May 15, 2026

**Re: Amendment No. 2**

Dear Mr. Regan:

Reference is made to the Directed Stock Purchase Agreement, dated as of January 16, 2026 (as modified to the date hereof, the "**Purchase Agreement**"), by and among CDT Equity, Inc., a Delaware corporation (together with its successors and permitted assigns, the "**Company**"), Ascent Partners Fund LLC, a Delaware limited liability company (**"Ascent**"); capitalized terms used but not defined herein are used as defined in the Purchase Agreement, including if defined by reference to definitions in other Transaction Documents).

The amendments set forth herein shall expire on May 31, 2026, and shall apply solely to Advance Notices delivered during the month of May 2026.

Subject to the terms and conditions set forth herein, and effective on the later of (i) the date hereof and (ii) the date of execution and delivery of this amendment by all parties listed on the signature pages hereof (the "**Amendment Effective Date**") , the following Transaction Documents are hereby amended as follows:

***Purchase Agreement***

 ****

● **Section 1.1 (c)(i)** of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) without
 the consent of the Purchaser, the Regular Purchase Price paid at any Closing shall not exceed
 $510,000.

● **Section 1.1 (c)(iii)** of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if
 the Pricing Percentage of the lowest VWAP for the Common Stock (the "**Adjusted Price** ")
 in the period starting on the Closing Date and ending on the date when the Purchaser shall
 have entered into committed, binding trades to sell all of the Purchased Securities purchased
 at such Regular Closing (the "**Adjustment Period**") is lower than such Regular
 Purchase Price per share, then the Company shall, on the trading day immediately following
 the end of the Adjustment Period, issue additional Purchased Securities (the "**Adjustment Securities**") to the Purchaser so as to ensure that the aggregate number of shares
 of Purchased Securities received by the Purchaser for such Regular Closing equals the number
 of shares it would have received if the Regular Purchase Price per share had been equal to
 the Adjusted Price.

This amendment is a Transaction Document and is limited as written.

As of the date first written above, each reference in the Purchase Agreement to "**this Agreement**," "**hereunder**," "**hereof**," "**herein**," or words of like import, and each reference in the other Transaction Documents to the Purchase Agreement (including, without limitation, by means of words like "**thereunder**," "**thereof**" and words of like import), shall refer to the Purchase Agreement as modified thereby, and the provisions in this amendment amending the Purchase Agreement shall be read together and construed as a single agreement with the Purchase Agreement. The execution, delivery and effectiveness of this amendment shall not, except as expressly provided herein, (A) waive or modify any Default or Event of Default (whether or not existing on the date hereof), right, power or remedy under, or any other provision of, any Transaction Document (in each case, other than any failure to comply with any provision of a Transaction Document amended hereby that would not have been a failure if such Transaction Document had been amended as provided herein prior to the date hereof) or (B) commit or otherwise obligate the Holder or the Collateral Agent to enter into or consider entering into any other consent, waiver or modification of any Transaction Document or make any further purchases or other advances pursuant to any Transaction Documents.

Each Company Party hereby agrees that it continues to guaranty, jointly and severally, absolutely, unconditionally and irrevocably, pursuant to the Guaranty, as primary obligor and not merely as surety, the full and punctual payment when due of the Obligations of any other Company Party owing under the Transaction Document as modified hereby (subject to the limitations set forth in the Guaranty) and that the terms hereof shall not affect in any way its obligations and liabilities, as expressly modified hereby, under the Transaction Documents. Each Company Party hereby reaffirms (a) all of its obligations and liabilities under the Transaction Documents as modified hereby, and agrees that such obligations and liabilities shall remain in full force and effect and (b) all Liens granted under the Transaction Documents, and agrees that such Liens shall continue to secure the Obligations.

In further consideration for the execution of this amendment by the Holder and without limiting any rights or remedies the Holder or any of its Related Parties may have, each Company Party hereby releases each of the Holder and each of its Related Parties (each a "**Releasee**" and, collectively, the "**Releasees**") against any and all claims and from any other Losses of any Company Party or any Subsidiary thereof, whether or not relating to any Transaction Document, any obligation or liability owing thereunder, any asset of any Company Party or any of their Subsidiaries or Affiliates, or any legal relationship that exists or may exist between any Releasee and any Company Party or any Subsidiary of any Company Party. Each Company Party, each for itself and for its Subsidiaries, acknowledges and agrees that it or its Subsidiaries may discover information later that could have affected materially their willingness to agree to the release in this paragraph and that neither such possibility, which it took into account when executing this amendment, nor such discovery, as to which it expressly assumes the risk, shall affect the effectiveness of the release in this paragraph, and waives the benefit of any legal requirement that may provide otherwise.

As a Transaction Document, this amendment is subject to various interpretative and miscellaneous sections set forth in the Purchase Agreement and other Transaction Documents that apply expressly to all Transaction Documents, located principally **Article V (Miscellaneous)** of the Purchase Agreement (but also, without limitation, in **Section 4.6 (Indemnification of Each Purchase Party)** thereof), including **Section 5.2 (Fees and Expenses)** thereof (which provides, without limitation, reimbursement to the Purchaser Parties for fees, costs and expenses of negotiation, preparation, execution and signing of this amendment or otherwise relating to this amendment or the transactions contemplated herein) and **Sections 5.3(a) (Entire Agreement), 5.3(b) (Amendments), 5.3(c) (Beneficiary, Successors and Assigns), 5.3(d) (No Implied Waivers or Notice Rights), 5.3(e) (Counterparts), Section 5.3(f) (Electronic Signatures)**, **5.4 (Notices), 5.8 (Severability) and 5.16 (Interpretation)** (containing various interpretative provisions and additional definitions) thereof. In addition, without limitation, (a) **Section 5.7 (Governing Law; Courts)** thereof provides that this amendment shall be governed by and construed in accordance with the laws of the State of Delaware and that Proceedings in respect hereto shall be brought exclusively in the Delaware state courts sitting in Wilmington, DE or the federal courts for the District of Delaware sitting in Wilmington, DE (subject to certain exceptions for enforcement Proceedings brought by the Collateral Agent or any Purchaser Party) and (b) in **Section 5.17 (Waiver of Jury Trial and Certain Other Rights)**, **the parties thereto (which include the parties hereto) thereby irrevocably and unconditionally waived, to the fullest extent permitted by applicable Regulations, any right that they may have to trial by jury of any claim or cause of action or in any Proceeding, directly or indirectly based upon or arising out of, under or in connection with, this amendment or the transactions contemplated therein or related thereto (whether founded in contract, tort or any other theory).** The parties hereto hereby reaffirm all of these and all other provisions of the Transaction Documents applying to the Transaction Documents as applying to this amendment, all of which are hereby incorporated herein by reference. If the Amendment Effective Date has not occurred within two Business Days after the date hereof, the Collateral Agent may, in its sole discretion upon notice to the Company, elect to terminate this amendment, at which point this amendment will be of no further force and effect.

***[*** ***Signature Pages Follow]***

![](ex10-1_002.jpg)

 ****

This amendment may be executed in counterparts, which may be effectively transmitted by fax or e-mail (in each case return receipt requested and obtained) and which, together, shall constitute one and the same instrument.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| ASCENT PARTNERS FUND LLC, | ASCENT PARTNERS FUND LLC, |
| as Holder | as Holder |
| By: | /s/ Mikhail Gurevich |
| Name: | Mikhail Gurevich |
| Title: | Authorized Signatory |

---

---

| | |
|:---|:---|
| Accepted and Agreed | Accepted and Agreed |
| As of the Date First Written Above: | As of the Date First Written Above: |
| CDT EQUITY INC., | CDT EQUITY INC., |
| as Company | as Company |
| By: | /s/ Jamie Bligh |
| Name: | Jamie Bligh |
| Title: | Authorized Officer |

---

![](ex10-1_002.jpg)

## Exhibit 10.2

**Exhibit 10.2**

![](ex10-2_001.jpg)

**19505 Biscayne Blvd. ● Suite 2350 ● Aventura, FL 33180 ● legal@ascentpartnersllc.com**

To:

CDT Equity Inc.

4851 Tamiami Trail North, Suite 200

Naples, Florida 34103

Attention: Andrew Regan <br> CEO

May 15, 2026

**Re: Amendment No. 1**

Dear Mr. Regan:

Reference is made to the Senior Secured Convertible Note, dated as of March 3, 2026 (as modified to the date hereof, the "**Note**"), by and among CDT Equity Inc., a Delaware corporation (together with its successors and permitted assigns, the "**Company**"), Ascent Partners Fund LLC, a Delaware limited liability company (**"Ascent**") and the other Purchasers from time to time party thereto and Ascent, as collateral agent for the Purchaser Parties, as defined therein (together with its successors and permitted assigns, the **"Collateral Agent"**); capitalized terms used but not defined herein are used as defined in the Note, including if defined by reference to definitions in other Transaction Documents.

The amendments set forth herein shall expire on May 31, 2026, and shall apply solely to Advance Notices delivered during the month of May 2026.

Subject to the terms and conditions set forth herein, and effective on the later of (i) the date hereof and (ii) the date of execution and delivery of this amendment by all parties listed on the signature pages hereof (the "**Amendment Effective Date**") , the following Transaction Documents are hereby amended as follows:

***Note***

 ****

● The first sentence of the **Section 1.1 (b)** of the Note is hereby amended and restated in its entirety to read as follows:

**Mandatory Prepayments.** On the next business day following any Company Party or any Subsidiary of any Company Party consummating any public or private offering or any other issuance of any Capital Stock or any other issuance of any Capital Stock (other than any issuance of Common Stock to the general public), Stock Equivalents or of any other Securities or Indebtedness (including entering into any Equity Line of Credit or issuing any Variable-Priced Equity-Linked Instrument) or any other debt or equity financing or capital-raising transaction of any kind (each a "**Subsequent Offering**") on any date other than the Maturity Date, the Company shall, subject to the Holder's conversion rights set forth herein, pay to the Holder in cash an amount equal to ten percent (10%) of the gross proceeds received by the Company from such Subsequent Offering, which amount shall be applied toward repayment of the outstanding Obligations.

This amendment is a Transaction Document and is limited as written.

As of the date first written above, each reference in the Note to **"this Note,"** "**hereunder**," "**hereof**," "**herein**," or words of like import, and each reference in the other Transaction Documents to the Note (including, without limitation, by means of words like "**thereunder**," "**thereof**" and words of like import), shall refer to the Note as modified thereby, and the provisions in this amendment amending the Note shall be read together and construed as a single agreement with the Note. The execution, delivery and effectiveness of this amendment shall not, except as expressly provided herein, (A) waive or modify any Default or Event of Default (whether or not existing on the date hereof), right, power or remedy under, or any other provision of, any Transaction Document (in each case, other than any failure to comply with any provision of a Transaction Document amended hereby that would not have been a failure if such Transaction Document had been amended as provided herein prior to the date hereof) or (B) commit or otherwise obligate the Holder or the Collateral Agent to enter into or consider entering into any other consent, waiver or modification of any Transaction Document or make any further purchases or other advances pursuant to any Transaction Documents. This amendment does not constitute a novation of the Note.

Each Company Party hereby agrees that it continues to guaranty, jointly and severally, absolutely, unconditionally and irrevocably, pursuant to the Guaranty, as primary obligor and not merely as surety, the full and punctual payment when due of the Obligations of any other Company Party owing under the Transaction Document as modified hereby (subject to the limitations set forth in the Guaranty) and that the terms hereof shall not affect in any way its obligations and liabilities, as expressly modified hereby, under the Transaction Documents. Each Company Party hereby reaffirms (a) all of its obligations and liabilities under the Transaction Documents as modified hereby, and agrees that such obligations and liabilities shall remain in full force and effect and (b) all Liens granted under the Transaction Documents, and agrees that such Liens shall continue to secure the Obligations.

In further consideration for the execution of this amendment by the Holder and without limiting any rights or remedies the Holder or any of its Related Parties may have, each Company Party hereby releases each of the Holder and each of its Related Parties (each a "**Releasee**" and, collectively, the "**Releasees**") against any and all claims and from any other Losses of any Company Party or any Subsidiary thereof, whether or not relating to any Transaction Document, any obligation or liability owing thereunder, any asset of any Company Party or any of their Subsidiaries or Affiliates, or any legal relationship that exists or may exist between any Releasee and any Company Party or any Subsidiary of any Company Party. Each Company Party, each for itself and for its Subsidiaries, acknowledges and agrees that it or its Subsidiaries may discover information later that could have affected materially their willingness to agree to the release in this paragraph and that neither such possibility, which it took into account when executing this amendment, nor such discovery, as to which it expressly assumes the risk, shall affect the effectiveness of the release in this paragraph, and waives the benefit of any legal requirement that may provide otherwise.

As a Transaction Document, this amendment is subject to various interpretative and miscellaneous sections set forth in the Purchase Agreement and other Transaction Documents that apply expressly to all Transaction Documents, located principally **Article V (Miscellaneous)** of the Purchase Agreement (but also, without limitation, in **Section 4.8 (Indemnification of Each Purchase Party)** thereof), including **Section 5.2 (Fees and Expenses)** thereof (which provides, without limitation, reimbursement to the Purchaser Parties for fees, costs and expenses of negotiation, preparation, execution and signing of this amendment or otherwise relating to this amendment or the transactions contemplated herein) and **Sections 5.3(a) (Entire Agreement), 5.3(b) (Amendments), 5.3(c) (Beneficiary, Successors and Assigns), 5.3(d) (No Implied Waivers or Notice Rights), 5.3(e) (Counterparts), Section 5.3(f) (Electronic Signatures)**, **5.4 (Notices), 5.7 (Severability) and 5.15 (Interpretation)** (containing various interpretative provisions and additional definitions) thereof. In addition, without limitation, (a) **Section 5.6 (Governing Law; Courts)** thereof provides that this amendment shall be governed by and construed in accordance with the laws of the State of Delaware and that Proceedings in respect hereto shall be brought exclusively in the Delaware state courts sitting in Wilmington, DE or the federal courts for the District of Delaware sitting in Wilmington, DE (subject to certain exceptions for enforcement Proceedings brought by the Collateral Agent or any Purchaser Party) and (b) in **Section 5.16 (Waiver of Jury Trial and Certain Other Rights)**, **the parties thereto (which include the parties hereto) thereby irrevocably and unconditionally waived, to the fullest extent permitted by applicable Regulations, any right that they may have to trial by jury of any claim or cause of action or in any Proceeding, directly or indirectly based upon or arising out of, under or in connection with, this amendment or the transactions contemplated therein or related thereto (whether founded in contract, tort or any other theory).** The parties hereto hereby reaffirm all of these and all other provisions of the Transaction Documents applying to the Transaction Documents as applying to this amendment, all of which are hereby incorporated herein by reference. If the Amendment Effective Date has not occurred within two Business Days after the date hereof, the Collateral Agent may, in its sole discretion upon notice to the Company, elect to terminate this amendment, at which point this amendment will be of no further force and effect.

***[Signature Pages Follow]***

 ****

This amendment may be executed in counterparts, which may be effectively transmitted by fax or e-mail (in each case return receipt requested and obtained) and which, together, shall constitute one and the same instrument.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| ASCENT PARTNERS FUND LLC, | ASCENT PARTNERS FUND LLC, |
| as Holder | as Holder |
| By: | /s/ Mikhail Gurevich |
| Name: | Mikhail Gurevich |
| Title: | Authorized Signatory |

---

---

| | |
|:---|:---|
| Accepted and Agreed | Accepted and Agreed |
| As of the Date First Written Above: | As of the Date First Written Above: |
| CDT EQUITY INC., | CDT EQUITY INC., |
| as Company | as Company |
| By: | /s/ Jamie Bligh |
| Name: | Jamie Bligh |
| Title: | Authorized Officer |

---

![](ex10-2_002.jpg)